Provided by Tiger Fintech (Singapore) Pte. Ltd.

ProQR Therapeutics NV

1.78
-0.0050-0.28%
Volume:131.63K
Turnover:230.76K
Market Cap:186.98M
PE:-4.88
High:1.79
Open:1.79
Low:1.73
Close:1.78
Loading ...

Oppenheimer Adjusts ProQR Therapeutics N.V Price Target to $9 From $15, Maintains Outperform Rating

MT Newswires Live
·
13 May

ProQR Therapeutics NV reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

ProQR Therapeutics Q1 EPS $(0.10) Misses $(0.09) Estimate, Sales $4.75M Beat $4.49M Estimate

Benzinga
·
08 May

ProQR Therapeutics NV expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
02 May

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

GlobeNewswire
·
01 May

ProQR Therapeutics initiated with an Outperform at Evercore ISI

TipRanks
·
30 Apr

ProQR Therapeutics Initiated at Outperform by Evercore ISI Group

Dow Jones
·
29 Apr

Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?

Zacks
·
15 Apr

ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 34%

Simply Wall St.
·
15 Apr

ProQR Appoints Dennis Hom as CFO, Cristina Lopez as CMO

MT Newswires Live
·
14 Apr

ProQR Therapeutics Names Hom as CFO, Lopez Lopez as Chief Medical Officer

Dow Jones
·
14 Apr

ProQR Therapeutics appoints Hom as CFO, Lopez as CMO

TIPRANKS
·
14 Apr

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

GlobeNewswire
·
14 Apr

ProQR Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
14 Mar

BRIEF-Proqr Therapeutics NV Files For Shelf Of Up To Up To 3.5 Million Ordinary Shares By Selling Stockholder - SEC Filing

Reuters
·
13 Mar

ProQR Therapeutics Nv Files for Shelf of up to up to 3.5 Mln Ordinary Shares by Selling Stockholder - SEC Filing

THOMSON REUTERS
·
13 Mar

ProQR FY24 EPS EUR(0.32) Up From EUR(0.35) YoY

Benzinga
·
13 Mar

ProQR Therapeutics Nv: EUR 149.4 Mln Cash and Cash Equivalents as of End of 2024, Providing Runway Into Mid-2027

THOMSON REUTERS
·
13 Mar

ProQR Announces Year End 2024 Operating and Financial Results

GlobeNewswire
·
13 Mar

Citigroup Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $4

MT Newswires Live
·
10 Mar